Trial Profile
A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjogren's Syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2018
Price :
$35
*
At a glance
- Drugs Tibulizumab (Primary)
- Indications Sjogren's syndrome
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 10 Dec 2018 Status changed from active, no longer recruiting to completed.
- 23 Aug 2018 Planned End Date changed from 1 Sep 2018 to 5 Sep 2018.
- 23 Aug 2018 Planned primary completion date changed from 1 Sep 2018 to 5 Sep 2018.